FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801862162> ?p ?o ?g. }

• W2801862162 endingPage "e0196350" @default.
• W2801862162 startingPage "e0196350" @default.
• W2801862162 abstract "Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) are indicated as first-line therapy in patients with non-small cell lung cancer (NSCLC) whose tumors harbor activating mutations in the EGFR gene. Erlotinib is also used in second and third-line therapy for patients whose tumors have wild type EGFR but to date there are no validated biomarkers useful to identify which patients may benefit from this treatment. The expression level of four miRNAs: miR-133b, -146a, -7 and -21 which target EGFR was investigated by real-time PCR in tumor specimens from NSCLC patients treated with erlotinib administered as the second or third line. We found that miR-133b expression level better discriminated responder from non-responder patients to erlotinib. Higher levels of miR-133b in NSCLCs were associated with longer progression-free survival time of patients. Functional analyses on miR-133b through transfection of a miR-133b mimic in A549 and H1299 NSCLC cell lines indicated that increasing miR-133b expression level led to a decreased cell growth and altered morphology but did not affect sensitivity to erlotinib. The detection of miR-133b expression levels in tumors help in the identification of NSCLC patients with a better prognosis and who are likely to benefit from second and third-line therapy with erlotinib." @default.
• W2801862162 created "2018-05-17" @default.
• W2801862162 creator A5011199591 @default.
• W2801862162 creator A5034220270 @default.
• W2801862162 creator A5034700693 @default.
• W2801862162 creator A5046162538 @default.
• W2801862162 creator A5058844594 @default.
• W2801862162 creator A5066200364 @default.
• W2801862162 creator A5066850001 @default.
• W2801862162 creator A5075086554 @default.
• W2801862162 creator A5080054746 @default.
• W2801862162 creator A5084568721 @default.
• W2801862162 date "2018-04-24" @default.
• W2801862162 modified "2023-10-13" @default.
• W2801862162 title "Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients" @default.
• W2801862162 cites W1497381120 @default.
• W2801862162 cites W1928520804 @default.
• W2801862162 cites W1967394241 @default.
• W2801862162 cites W1976672798 @default.
• W2801862162 cites W1984098997 @default.
• W2801862162 cites W1987409881 @default.
• W2801862162 cites W1990261439 @default.
• W2801862162 cites W1999250507 @default.
• W2801862162 cites W2006797972 @default.
• W2801862162 cites W2009512005 @default.
• W2801862162 cites W2016700676 @default.
• W2801862162 cites W2030864655 @default.
• W2801862162 cites W2037011799 @default.
• W2801862162 cites W2037791152 @default.
• W2801862162 cites W2051224169 @default.
• W2801862162 cites W2054805907 @default.
• W2801862162 cites W2074201366 @default.
• W2801862162 cites W2097026987 @default.
• W2801862162 cites W2110666579 @default.
• W2801862162 cites W2111662961 @default.
• W2801862162 cites W2126277347 @default.
• W2801862162 cites W2129360604 @default.
• W2801862162 cites W2132157071 @default.
• W2801862162 cites W2134045615 @default.
• W2801862162 cites W2134964659 @default.
• W2801862162 cites W2135192471 @default.
• W2801862162 cites W2135507887 @default.
• W2801862162 cites W2150923784 @default.
• W2801862162 cites W2152995571 @default.
• W2801862162 cites W2154662831 @default.
• W2801862162 cites W2160982674 @default.
• W2801862162 cites W2166084034 @default.
• W2801862162 cites W2251438188 @default.
• W2801862162 cites W2329185469 @default.
• W2801862162 cites W2399686786 @default.
• W2801862162 cites W2410792732 @default.
• W2801862162 cites W2510701086 @default.
• W2801862162 cites W2516905666 @default.
• W2801862162 cites W2625018508 @default.
• W2801862162 cites W4238271314 @default.
• W2801862162 cites W4244640572 @default.
• W2801862162 doi "https://doi.org/10.1371/journal.pone.0196350" @default.
• W2801862162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5916492" @default.
• W2801862162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29689091" @default.
• W2801862162 hasPublicationYear "2018" @default.
• W2801862162 type Work @default.
• W2801862162 sameAs 2801862162 @default.
• W2801862162 citedByCount "16" @default.
• W2801862162 countsByYear W28018621622019 @default.
• W2801862162 countsByYear W28018621622020 @default.
• W2801862162 countsByYear W28018621622021 @default.
• W2801862162 countsByYear W28018621622022 @default.
• W2801862162 countsByYear W28018621622023 @default.
• W2801862162 crossrefType "journal-article" @default.
• W2801862162 hasAuthorship W2801862162A5011199591 @default.
• W2801862162 hasAuthorship W2801862162A5034220270 @default.
• W2801862162 hasAuthorship W2801862162A5034700693 @default.
• W2801862162 hasAuthorship W2801862162A5046162538 @default.
• W2801862162 hasAuthorship W2801862162A5058844594 @default.
• W2801862162 hasAuthorship W2801862162A5066200364 @default.
• W2801862162 hasAuthorship W2801862162A5066850001 @default.
• W2801862162 hasAuthorship W2801862162A5075086554 @default.
• W2801862162 hasAuthorship W2801862162A5080054746 @default.
• W2801862162 hasAuthorship W2801862162A5084568721 @default.
• W2801862162 hasBestOaLocation W28018621621 @default.
• W2801862162 hasConcept C121608353 @default.
• W2801862162 hasConcept C126322002 @default.
• W2801862162 hasConcept C143998085 @default.
• W2801862162 hasConcept C2776256026 @default.
• W2801862162 hasConcept C2778087573 @default.
• W2801862162 hasConcept C2779438470 @default.
• W2801862162 hasConcept C2780580887 @default.
• W2801862162 hasConcept C2780586478 @default.
• W2801862162 hasConcept C2909325608 @default.
• W2801862162 hasConcept C502942594 @default.
• W2801862162 hasConcept C71924100 @default.
• W2801862162 hasConcept C86803240 @default.
• W2801862162 hasConceptScore W2801862162C121608353 @default.
• W2801862162 hasConceptScore W2801862162C126322002 @default.
• W2801862162 hasConceptScore W2801862162C143998085 @default.
• W2801862162 hasConceptScore W2801862162C2776256026 @default.
• W2801862162 hasConceptScore W2801862162C2778087573 @default.
• W2801862162 hasConceptScore W2801862162C2779438470 @default.

• next